

# Mary P. Stenzel-Poore, Ph.D

## Curriculum Vitae

Department of Molecular Microbiology and Immunology, L220  
Oregon Health & Science University  
3181 SW Sam Jackson Park Road  
Portland, OR 97239-3098  
Tel: 503-494-2423 FAX: 503-494-6862  
E-mail: poorem@ohsu.edu

### EDUCATION

1989-1992 The Salk Institute for Biological Studies Postdoctoral Fellowship.  
1986-1988 Oregon Health Sciences Univ. Postdoctoral Fellowship  
1982-1986 Oregon Health Sciences Univ. PhD Graduate program (Immunology)  
1972-1976 Lewis and Clark College, Bachelors of Science in Biology

### PROFESSIONAL EXPERIENCE

2012- present Sr. Associate Dean for Research, School of Medicine, OHSU  
2012-present Associate Vice President for Basic Research, OHSU  
2010-present Chair, Molecular Microbiology and Immunology, OHSU  
2008-present Associate Dean for Basic Sciences, School of Medicine, OHSU  
2008-present Affiliate Senior Scientist, Neuroscience, Pathobiology and Immunology, ONPRC  
2007-2010 Interim Chair, Molecular Microbiology and Immunology, OHSU  
2006-present Professor, Molecular Microbiology and Immunology, OHSU  
2002-2008 Director of Graduate Student Program, Molecular Microbiology & Immunology, OHSU  
2002-2009 OHSU School of Medicine MD/PhD Committee  
2001-2006 Associate Professor, Molecular Microbiology and Immunology, OHSU  
1997— OHSU Heart Research Center Scientist  
1996— OHSU Neuroscience Graduate Program Faculty Member  
1995 Assistant Professor, Molecular Microbiology and Immunology, OHSU  
1993 Research Assistant Professor, Molecular Microbiology and Immunology, OHSU  
1989 Postdoctoral Fellowship, The Salk Institute for Biological Studies  
1988 Instructor, Microbiology and Immunology, OHSU  
1986 Postdoctoral Fellowship, OHSU  
1982 Graduate Student, OHSU

### AWARDS

Tartar Research Fellowship, 1984  
American Heart Association Corporate Award (Local Affiliate) 1995  
Medical Research Foundation Award, 1993-1994  
Individual National Research Service Award, 1989-1992

### PROFESSIONAL SOCIETY MEMBERSHIPS

2002-present Society for Neuroscience  
1990-2009 American Association of Immunologists  
1998-2008 The Endocrine Society  
1998-2008 International Society for Neuroimmunology

### PROFESSIONAL REVIEW COMMITTEES

NINDS Stroke Progress Review Group (Defining Disease I (Genomics, Proteomics), 2001  
University California, San Francisco, Neuroscience Program Review

#### Grant Review

2006-present Medical Research Foundation Council  
2005-present Brain Injuries and Neurovascular Pathologies (BDCN-L), NIH (ad hoc member)

- 2004-present Chair of Review: NINDS Specialized Neuroscience Research Program for Under-represented Minorities, NIH
- 2002-2007 Training Grant and Career Development Study Section (NST 1)
- 2000-2005 Endocrinology Study Section, NIH (ad hoc member)
- 1999-2002 OHSU School of Medicine Research Committee
- 1998, 2002 Welcome Trust Special Review:
- 1999 Murdock College Research Program, ad hoc reviewer
- 1997-1999 American Cancer Society (Local Affiliate) Grant Review
- 1994, 1996 National Institutes of Mental Health Special Review Panel
- 1995 Hong Kong Research Grants Council Special Review Panel

**Manuscript Review**

- 2006-present Stroke Editorial Board
- 2004-present Journal of Cerebral Blood Flow and Metabolism, invited reviewer
- 1999-present Peptides (Journal), invited reviewer
- 1999-present Journal of Neuroscience, invited reviewer
- 2000-2004 Endocrinology Editorial Board
- 1995-1999 Endocrinology (Journal), invited reviewer

**FEDERAL GRANTS (CURRENT)**

R01 NS062381 NIH/NINDS Stenzel-Poore (PI) 04/15/2009 – 03/31/2014  
*Toll-like Receptors: Novel targets of neuroprotection in ischemic brain injury*  
The goal of this project is to characterize the use of prophylactic TLR stroke therapy using TLR 7 and TLR 9 agonists. We will address the potential mechanisms that underlie neuroprotection and whether these mechanisms act systemically and/or are located in the CNS.

1U01 NS064953-01 NIH/NINDS Stenzel-Poore (PI) 04/01/2009—02/28/2015  
*Development of Toll-like receptor agonists as neuroprotectants in brain ischemia.*  
The goal of this application is to develop TLR agonists as neuroprotectants in a preclinical model of nonhuman primate stroke. Studies will address optimal dosing and time windows for candidate molecules, as well as gender and age effects on stroke outcome.

R01 NS050567 NIH/NINDS Stenzel-Poore (PI) 07/01/2011 – 06/30/2016  
*Molecular Mechanisms of LPS Preconditioning in Stroke.* The primary goal of this project is to investigate LPS preconditioning in stroke and define the specific molecular pathways that subserve this neuroprotective process.

**OTHER**

- Patents Awarded:  
Corticotropin-releasing factor overproducing mice. #S93011, US serial #08/068,754.
- Patents Provisional:  
Methods useful in the treatment of cytotoxic insult. US Patent Application #61/524,696
- NeuroAlexo™ : Founding Scientist, Biotechnology Startup Company, OHSU spin-off

**INVITED LECTURES, CONFERENCE PRESENTATIONS OR PROFESSORSHIPS:**

**International and National**

- 1994 American College of Neuropsychopharmacology 32nd Annual Meeting, Honolulu, Hawaii
- 1995 Summer Neuropeptide Conference, Martha's Vineyard, MA
- 1995 American Association of Immunologists, International Conference, San Francisco, CA\*
- 1996 Fred Hutchinson Cancer Research Center, Seattle, WA
- 1996 Dupont Merck, Research and Development, Wilmington, DE
- 1997 Endocrine Society Annual meeting, Minneapolis, MN\*
- 1998 National Institute for Occupational Safety and Health, Morgantown, West Virginia

- 1998 Max Planck Institute, Munich, Germany
- 1998 Endocrine Society Annual meeting, New Orleans, LA\*
- 1999 Steroid Hormones and Brain Function, Breckenridge, CO
- 1999 Endocrine Society Annual meeting, San Diego, CA\*
- 2000 Zymogenetics, Seattle, WA
- 2000 Endocrine Society Annual meeting, Toronto, Canada\*
- 2000 Society for Neuroscience, Special Interest Panel-Neuroimmunology, New Orleans, LA
- 2001 International Pituitary Congress, Phoenix Arizona
- 2001 Ohio State University, Dept. of Oral Biology, Columbus, OH
- 2001 Research Society of Alcoholism, Montreal, Canada
- 2001 University of Washington, Department of Pathology, Seattle, WA
- 2002 9<sup>th</sup> International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany
- 2002 Spring Hippocampal Research Conference, Grand Cayman, British West Indies
- 2003 7<sup>th</sup> Annual HypoCCS Symposium, Prague, Czech Republic
- 2003 CRH-ACTH Annual Meeting, Osaka, Japan
- 2003 6<sup>th</sup> European Congress of Endocrinology, Lyon, France
- 2003 Invited lecture to Shanghai Pathology Branch of the Chinese Medical Association, Shanghai, China
- 2004 University of California, Dept of Neuroscience, Irvine
- 2004 University of Vermont, Neurology Dept., Visiting Professor, Neuroscience Grand Rounds
- 2004 24<sup>th</sup> Princeton Conference on Cerebral Vascular Disease, Baltimore, Maryland
- 2004 University of Calgary, 12<sup>th</sup> Annual Medical Sciences Graduate Student Association Symposium
- 2004 10<sup>th</sup> International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany
- 2004 Tiantan International Stroke Conference, Beijing, China
- 2004 International Symposium for Neurological Diseases, Shanghai, China
- 2004 National Institute of Neurological Diseases and Stroke Seminar Series, NIH, Bethesda, Maryland
- 2006 University of Alaska, Arctic Biology Institute, Fairbanks, AK
- 2006 American Society of Neurochemistry, Portland, OR
- 2006 25<sup>th</sup> Princeton Conference on Cerebral Vascular Disease, Portland, OR
- 2006 6<sup>th</sup> Annual Conference on Specialized Neuroscience Research Program, Fairbanks, AK
- 2006 Neurodegeneration and Neuroprotection, Muenster, Germany
- 2006 Second Rome Stroke Conference, Rome, Italy
- 2007 University of California San Francisco, Neurology Department Grand Rounds
- 2008 6<sup>th</sup> World Stroke Conference, Vienna, Austria
- 2008 26<sup>th</sup> Princeton Conference on Cerebrovascular Disease, Houston, Texas
- 2009 Spring Hippocampal meeting, Verona, Italy
- 2009 International Stroke Conference, San Diego, CA
- 2009 American Society for Neurochemistry, Charleston NC
- 2011 Marquam Hill Lecture, Portland Oregon
- 2013 Cerebrovascular Research Update Symposium, Iowa City IA

#### Regional and Local

- 1996 Oregon Health Sciences University, Dept. of Cell and Developmental Biology, Portland, OR
- 1997 Lewis and Clark College, Dept. of Biology, Portland, OR
- 1997 Oregon Health Sciences University, Dept. of Physiology and Pharmacology, Portland, OR
- 1997 Oregon Graduate Institute, Beaverton, OR
- 1997 Oregon Regional Primate Research Center, Beaverton, OR
- 1999 OHSU Molecular Biology Colloquium, Portland, OR
- 2000 Robert S. Dow Neurobiology Research Institute, Portland, OR
- 2002 Oregon State University, Center for Gene Research and Biotechnology, Corvallis, OR
- 2002 OHSU-Oregon Center for Complementary and Alternative Medicine, Portland, OR
- 2005 Oregon Health and Science University, Neurology Grand Rounds, Portland, OR
- 2013 Achievement Rewards for College Scientists, Portland, OR

\*Based on abstracts submitted

**SERVICE:**

**International/National**

2001 NINDS Stroke Progress Review Group (Defining Disease I (Genomics, Proteomics))  
 1998, 2002 Welcome Trust Special Review

**Local (Institutional)**

2005-2008 Committee on Committees (OHSU)  
 2004-present Medical Research Foundation and Education Committee  
 2004-present School of Medicine Graduate Bylaws Committee  
 2004-present Faculty Senate  
 2002-present MD/PhD Admissions Committee  
 2000-2005 School of Medicine Outstanding Paper Awards Committee  
 2000-2003 Heart Center Research Committee (Chair)  
 2000-2003 Neuroscience Graduate Student Admissions Committee  
 1999 Heart Research Center Priorities Committee  
 1998-present School of Medicine Admissions Interview Committee  
 1998 Physiology/Pharmacology Chair Search Committee  
 1998-1999 Congenital Heart Research Center Funding Committee  
 1995-1997 Molecular and Cellular Biology Program Fellowship Awards

**Local (Departmental)**

2001-present Graduate Qualifying Exam Committee, Chair  
 2001-2006 Director, Molecular Microbiology and Immunology Graduate Program  
 1997-2003 Annual Retreat Co-Organizer  
 1996-present Molec. Microbiology & Immunology Training Grant Fellowship Awards

**Community Service:**

**National**

2005-2006 Princeton Conference Scientific Session Organizer  
 2005-2006 American Society for Neurochemistry, Scientific Session Organizer  
 2005-present Brain Injuries and Neurovascular Pathologies (BDCN-L) study section, NIH.  
 2004-2010 Chair NIH Review Special Neuroscience Research Program for Under-represented Minorities  
 2002-present NINDS Training Grant and Career Development Study Section (NST 1), NIH.  
 2001 NINDS Stroke Progress Review Group (Defining Disease I (Genomics, Proteomics))  
 2000-2002 Endocrinology Study Section, NIH.  
 2000-2004 *Endocrinology* Editorial Board.  
 1999 Murdock College Research Program, ad hoc reviewer.  
 1997-2000 American Cancer Society (Local Affiliate) Grant Review.  
 1995-1999 *Endocrinology* (Journal): ad hoc reviewer.  
 1995 Hong Kong Research Grants Council Special Review Panel.  
 1994, 1996 National Institutes of Mental Health Special Review Panel.

**Local**

2009-present OHSU Research Council  
 2010-present OHSU Brain Institute Leadership Committee  
 2004-present Medical Research Foundation Research and Education Committee  
 2002-present Legacy Research Promotion Committee  
 2000-present OHSU School of Medicine Research Committee  
 2000 Science Mentoring Program for High School Students  
 1999 OMSI Brainstorm Program, science mentoring of elementary education teachers  
 1999 Volunteer Science Teacher: Arbor School of Arts and Science  
 1998 Evaluator for Beaverton High School Science Fair  
 1997 Mentor to Beaverton High School Advanced Biology Class

1997 Faculty Speaker in Current Topics in Science. Lewis and Clark College.  
1996 Scientific Advisor: Federal Court Judge R. E. Jones: silicone breast implant litigation.

## PUBLICATIONS

1. Keller, F.S., N. R. Niles, J. Rosch, C. T. Dotter and **Stenzel-Poore MP**. Retrograde pancreatic venography: autopsy study. *Radiology* 135:285-293, 1980.
2. Brown, M., **Stenzel-Poore MP** and M. B. Rittenberg. Immunologic memory to phosphocholine. VII. Lack of T15 VI gene utilization in Xid anti-PC hybridomas. *J. Immunol.* 135:3558-3563, 1985.
3. **Stenzel-Poore MP**, L. M. Hallick, J. L. Fendrick, M. Neuberger, F. J. Storrs and J. Hanifin. Herpes simplex virus shedding in genital secretions. *Sexually Transmitted Diseases* 14:17-22, 1987.
4. **Stenzel-Poore MP**, T.J. Hall, C. H. Heusser, C. H. Faust and M. B. Rittenberg. Immunologic memory to PC-KLH: Participation of the Q52 VH gene family. *J. Immunol.* 139:1698-1703, 1987.
5. **Stenzel-Poore MP** and M. B. Rittenberg. Immunoglobulin variable region heptamer-nonamer signal sequence joined to rearranged D-J segment: implications for the immunoglobulin recombinase mechanism. *J. Immunol.* 138: 3055-3059, 1987.
6. **Stenzel-Poore MP**, M. B. Rittenberg. V gene diversity in the memory response to PC-KLH. In: *H-2 Antigens: Genes, Molecules, Function.* 144: 827-835, 1987.
7. **Stenzel-Poore MP**, U.B. Bruderer, and M. B. Rittenberg. The adaptive potential of the memory response: clonal recruitment and epitope recognition. *Immunol. Rev.* 105:113-136, 1988.
8. **Stenzel-Poore MP** and M. B. Rittenberg. Clonal diversity, somatic mutation and immune memory to phosphocholine-KLH. *J. Immunol.* 143: 4123-4133, 1989.
9. Bruderer, U., **Stenzel-Poore MP**, H-P Bachinger, J. H. Fellman, and M.B. Rittenberg. Antibody combining site heterogeneity within the response to phosphocholine keyhole limpet hemocyanin. *Molec. Immunol.* 26:63-71, 1989.
10. **Stenzel-Poore MP** and M. B. Rittenberg. Unequal distribution of replacement mutations in  $\kappa$  and  $\lambda$  light chains and their associated H chains: the Group II antibody response to phosphocholine-KLH. in *Somatic Mutation in V regions*, ed, E. J. Steele, CRC Press. 1990.
11. Chen, Q., **Stenzel-Poore MP** and M.B. Rittenberg. Natural Auto- and polyreactive antibodies differing from antigen-induced antibodies in the H chain CDR3. *J. Immunol* 147:2359-2367, 1991.
12. **Stenzel-Poore MP**, K. Heldwein, P. Stenzel, S. Lee and W. W. Vale. Characterization of the genomic corticotropin-releasing factor gene from *Xenopus laevis*: two members of the CRF family exist in amphibians. *Molec. Endo.*, 6:1716-1724, 1992.
13. **Stenzel-Poore MP**, A. V. Cameron, J. Vaughan, P. E. Sawchenko and W.W. Vale. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. *Endocrinology*, 130:3378-3386, 1992.
14. Brown, M., **Stenzel-Poore MP**, S. Stevens, S. K. Kondoleon, J. Ng, H. P. Bachinger, and M.B. Rittenberg. Immunological memory to PC-KLH: recurrent mutations in the  $\lambda 1$  light chain increase affinity for antigen. *J. Immunol.*, 148:339-346, 1992.
15. **Stenzel-Poore MP**, W. W. Vale, and C. Rivier. Relationship between antigen-induced immune stimulation and activation of the HPA axis in the rat. *Endocrinology*, 132: 1313-1318, 1993.
16. **Stenzel-Poore MP**, S. C. Heinrichs, S. Rivest, G. F. Koob and W. W. Vale. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior. *J. Neurosci.* 14: 2579-2584, 1994.
17. Stenzel, P., R. Kesterson, W. Yeung, R.Cone, M.B. Rittenberg and **Stenzel-Poore MP**. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. *Molec. Endo.* 9:637-645, 1995.
18. Chen, C., V. A. Roberts, S. Stevens, **Stenzel-Poore MP** and M.B. Rittenberg. Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. *EMBO J.* 14:2784-2794, 1995.
19. Heinrichs, S. C., **Stenzel-Poore MP**, L. H. Gold, E. Battenberg, F. E. Bloom, G. F. Koob, W. W. Vale and E. M. Pich. Learning impairment in transgenic mice with central overexpression of corticotropin-releasing factor. *Neuroscience* 74: 303-311, 1996.

20. Heldwein K.A., D. L. Redick, M. B. Rittenberg, W. C. Claycomb and **Stenzel-Poore MP**. Corticotropin-releasing hormone receptor expression and functional coupling in neonatal cardiac myocytes and AT-1 Cells. *Endocrinology* 137:3631-3639, 1996.
21. **Stenzel-Poore MP**, J. E. Duncan, M. B. Rittenberg, A. C. Bakke and S. C. Heinrichs. CRH overproduction in transgenic mice: behavioral and immune system modulation. *Ann NY Acad. Sci.*, 780: 36-48, 1996.
22. Martin, T.M., Kowalczyk, C., Stevens, S., Weins, G.D., **Stenzel-Poore MP** and Rittenberg, M.B. Deletion in HCDR3 rescues T15 antibody mutants from a secretion defect caused by mutations in CDR2. *J. Immunol.* 157:4341-4346, 1996.
23. Wiens, G.D., K. A. Heldwein, **Stenzel-Poore MP** and M. B. Rittenberg. Somatic mutation in V<sub>H</sub>CDR2 and FRW2: Differential effects on antigen binding and immunoglobulin secretion. *J. Immunol.* 159:1293-1302, 1997.
24. Heldwein, K. A., J. E. Duncan, P. Stenzel, M.B. Rittenberg and **Stenzel-Poore MP**. Endotoxin regulates corticotropin-releasing hormone receptor 2 (CRH-R2) in heart and skeletal muscle. *Molec. Cell. Endo.* 131:167-172, 1997.
25. Wiens, G.D., V.A. Roberts, E.A. Whitcomb, T. O'Hare, **Stenzel-Poore MP**, M.B. Rittenberg. Harmful somatic mutations: lessons from the dark side. *Immunol. Reviews*, 162:197-209, 1998.
26. Hill, J. K., L. Gunion-Rinker, D. Kulhanek, N. Lessov, S. Kim, W. Clark, R. Nishi, **Stenzel-Poore MP\***, F. P. Eckenstein\*. Temporal modulation of cytokine expression following focal cerebral ischemia in mice. *Brain Res.* 820:45-54, 1999 (\* co-senior authors).
27. Brown, M., GD Wiens, T. O'Hare, **Stenzel-Poore MP**, M. B. Rittenberg. Replacements in the exposed loop of the T15 antibody V<sub>H</sub> CDR2 affect carrier recognition of PC-containing pathogens. *Molec. Immunol.* 36:205-211, 1999.
28. Coste S, RA Kesterson, KA Heldwein, SL Stevens, JK Hill, AD Heard, SE Murray, GA Pantely, AR Hohimer, DC Hatton, TJ Phillips, DA Finn, MJ Low, MB Rittenberg, P Stenzel, **Stenzel-Poore MP**. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. *Nature Genet.* 24:403-409, 2000.
29. Clark W.M., L.G. Rinker, N. S. Lessov, K. Hazel, J. Hill, **Stenzel-Poore MP**, F. Eckenstein. Lack of IL-6 expression is not protective against focal CNS ischemia. *Stroke* 31: 1715-1720, 2000.
30. Coste SC, Heldwein KA., Stevens SL, Tobar-Dupres E, **Stenzel-Poore MP**. IL-1 and TNF- $\alpha$  downregulate corticotropin-releasing hormone receptor-2 mRNA expression in the mouse heart. *Endocrinology*, 142: 3537-3545, 2001.
31. Murray SE, Lallman HR, Heard AM, Rittenberg MB, **Stenzel-Poore MP**. A genetic mouse model of stress: decreased lymphocytes and impaired antibody responses without altered susceptibility to *S. pneumoniae*. *J. Immunol.* 167:691-698, 2001.
32. Preil J, Müller, M, Gesing A, Reul JM., Sillaber I, van Gaalen M, Landgrebe J, Holsboer F, **Stenzel-Poore MP**, Wurst W. Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for corticotropin-releasing hormone receptor 1 and 2. *Endocrinology*, 142:4946-4955, 2001.
33. Coste SC, Murray SE, **Stenzel-Poore MP**. Animal models of CRH excess and CRH receptor deficiency display altered adaptations to stress. *Peptides*, 22:733-741, 2001.
34. Stevens SL, Bao J, Hollis J, Lessov NS, Clark W, **Stenzel-Poore MP**. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. *Brain Res.* 932:110-119 2002.
35. Coste SC, Quintos RF, **Stenzel-Poore MP**. Corticotropin-releasing hormone related peptides and receptors: emergent regulators of cardiovascular adaptations to stress. *Trends in Cardio. Med.* 12:176-182, 2002.
36. van Gaalen M., **Stenzel-Poore, MP**, Holsboer F., Steckler, T. Effects of transgenic overproduction of CRH on anxiety-like behavior. *Eur. J. Neurosci.* 15:2007-2015, 2002.
37. van Gaalen M., Reul JM., Gesing A, **Stenzel-Poore MP**, Holsboer F, Steckler T. Mice overexpressing CRH show reduced responsiveness in plasma corticosterone after a 5-HT<sub>1A</sub> receptor challenge. *Genes, Brain, Behav.* 1:174-177, 2002.
38. Doyle KP, Simon RP, Snyder A, **Stenzel-Poore MP**. Working with GFP in the brain. *BioTechniques*: Vol.34:492-494, 2003.
39. van Gaalen M, **Stenzel-Poore MP**, Holsboer F, Steckler T. Reduced attention in mice overproducing corticotropin-releasing hormone. *Behav Brain Res.* 142:69-79, 2003.

40. **Stenzel-Poore MP**, Stevens SL, Xiong Z, Lessov N, Harrington CA, Mori M, Meller R, Rosenzweig H, Tobar E, Shaw T, Chu X, Simon, RP. Ischemic preconditioning reprograms the genomic response to cerebral ischemia and mimics neuroprotective strategies reported to occur in hibernation. *The Lancet* 362:1028-1037, 2003.
41. Stevens SL, Shaw TE, Dykhuizen E, Lessov NS, Hill JK, Wurst W, **Stenzel-Poore MP**. Reduced cerebral injury in CRH-R1 deficient mice after focal ischemia: A potential link to microglia and astrocytes that express CRH-R1. *J. Cereb Blood Flow*, 23:1151-1159, 2003.
42. Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB, Tarnopolsky M, Sheldon RJ, Coste SC, Tobar E, **Stenzel-Poore MP**, Isfort RJ. Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions. *Am J Physiol Endocrinol Metab* 285:E889-E898, 2003.
43. Hentges ST, Nishiyama M, Overstreet LS, **Stenzel-Poore M**, Williams JT, Low MJ. GABA release from proopiomelanocortin neurons. *J. Neurosci.*, 24:1578-1583, 2004.
44. Murray SE, Rosenzweig HL, Huising MO, Sawacki K, **Stenzel-Poore MP**. Overproduction of corticotropin-releasing hormone blocks germinal center formation: role of corticosterone and impaired follicular dendritic cell networks. *J. Neuroimmunol*, 156:31-41, 2004.
45. **Stenzel-Poore MP**, Stevens SL, Simon RP. Genomics of preconditioning, *Stroke*, 35:2683-2686, 2004.
46. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, **Stenzel-Poore MP**. Endotoxin preconditioning prevents the cellular inflammatory response during ischemic neuroprotection in mice. *Stroke*, 35:2576-2581, 2004.
47. Peeters PJ, Frederik LP, Fierens, Wyngaert I, Hinrich W, Goehlmann, Swagemakers SM, Kass SU, Langlois X, Pullan S., **Stenzel-Poore MP**, Steckler T. Gene expression profiles highlight adaptive brain mechanisms in corticotropin releasing factor overexpressing mice. *Molecular Brain Research* 129:135-150, 2004.
48. Palmer AA, Sharpe AL, Burkhart-Kasch S, McKinnon CS, Coste SC, **Stenzel-Poore MP**, Phillips TJ. Corticotropin releasing factor overexpression decreases ethanol drinking and increases sensitivity to the sedative effects of ethanol. *Psychopharm*, 176: 386-397, 2004.
49. Meller R, Stevens SL, Minami M, Cameron JA, King S, Rosenzweig HL, Doyle K, Lessov NS, Simon RP, **Stenzel-Poore MP**. Neuroprotection by osteopontin in stroke, *J Cereb. Blood Flow Metab.* 25:217-225, 2005.
50. Sharpe AL, Coste SC, Burhart-Kasch S, Li N, **Stenzel-Poore MP**, Phillips TJ. Mice deficient in corticotropin-releasing factor receptor type-2 (CRF2) exhibit normal ethanol-associated behaviors, *Alcoholism: Clinical and Experimental Research.* 29(9): 1601-1609, 2005.
51. Coste SC, Heard A, Phillips TJ, **Stenzel-Poore MP**. Corticotropin-releasing hormone receptor type-2 deficient mice show impaired behavioral responses during stress. *Genes, Brain and Behavior.* 5:131-138, 2006.
52. Stevens SL and **Stenzel-Poore MP**. Toll-like receptors and tolerance to ischaemic injury in the brain. *Biochem Soc Trans* 34:1352-1355, 2006.
53. **Stenzel-Poore MP**, Stevens SL, King JS, Simon RP. Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: A speculative synthesis. *Stroke*, 38:680-685, 2007.
54. Yao M, Stenzel-Poore M, Denver RJ. Structural and functional conservation of vertebrate corticotropin-releasing factor genes: evidence for a critical role for a conserved cyclic AMP response element. *Endocrinology*, 148:2518-2531, 2007.
55. Rosenzweig HL, Minami M, Lessov NS, Coste S, Stevens SL, Henshall DC, Meller R, Simon RP, **Stenzel-Poore MP**. Endotoxin preconditioning protects against the cytotoxic effects of TNF $\alpha$  following stroke: A novel role for TNF $\alpha$  in LPS-ischemic tolerance. *J Cereb Blood Flow Metab.* 27:1663-74, 2007.
56. Deussing JM, Kuhne C, Putz B, Panhuysen M, Breu J, **Stenzel-Poore MP**, Holsboer F, Wurst W. Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity. *J Cereb Blood Flow Metab*, 27:1476-95, 2007.
57. Million M, Wang L, **Stenzel-Poore MP**, Coste SC, Yuan PQ, Lamy C, Rivier J, Buffington T, Tache Y. Enhanced pelvic responses to stressors in female CRF-overexpressing mice. *Am J Physiol Regul Integr Comp Physiol.* 292:R1429-38, 2007.

58. Doyle K, Suchland KL, Ciesielski T, Lessov NS, Grandy DK, Scanlan TS, **Stenzel-Poore MP**. Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury. *Stroke*, 38:2569-2576, 2007.
59. Hickey EJ, You X, Kaimaktchiev V, **Stenzel-Poore M**, Ungerleider RM. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. *J Thorac Cardiovasc Surg*. 133:1588-96, 2007.
60. Stevens SL, Ciesielski T, Marsh BJ, Yang T, Homen D, Lessov N, Simon RP, **Stenzel-Poore MP**. Toll-like receptor 9: A new target of ischemic preconditioning in the brain. *J Cereb Blood Flow Metab*, 28(5): 1040-1047, 2008.
61. Doyle, KP, Yang, T, Lessov, NS, Ciesielski, TMP, Stevens, SL, Simon, RS, King, JS, **Stenzel-Poore, MP**. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. *J. Cereb Blood Flow Metab.*, 28:1235-48, 2008.
62. Pastor R, McKinnon CS, Scibelli AC, Burkhart-Kasch S, Reed C, Ryabinin AE, Coste SC, **Stenzel-Poore MP**, Phillips TJ. Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: a urocortin1-independent mechanism. *Proc Natl Acad Sci U S A* 105:9070-5, 2008.
63. Stengel A, Goebel M, Million M, **Stenzel-Poore MP**, Kobelt P, Mönnikes H, Taché Y, Wang L. CRF over-expressing mice exhibit reduced neuronal activation in the arcuate nucleus and food intake in response to fasting. *Endocrinology* 150:153-60.2009.
64. Marsh BJ, Stevens SL, Hunter B, **Stenzel-Poore MP**. Inflammation and the emerging role of the Toll-Like Receptor system in acute brain Ischemia. *Stroke*. 40:S34-S37, 2009.
65. West GA, Golshani KJ, Doyle KP, Lessov NI, Hobbs TR, Kohama SG, Pike MM, Kroenke CD, Grafe MR, Spector MD, Tobar ET, Simon RP, **Stenzel-Poore MP**. A new model of cortical stroke in the rhesus macaque. *J. Cerebral Blood Flow & Metabolism*, 29(6):1175-86, 2009.
66. Beckstead MJ, Gantz SC, Ford CP, **Stenzel-Poore MP**, Phillips PE, Mark GP, Williams JT. CRF enhancement of GIRK channel-mediated transmission in dopamine neurons. *Neuropsychopharmacology* 34:1926-35, 2009.
67. Risbrough VB, Geyer MA, Hauger RL, Coste S, **Stenzel-Poore M**, Wurst W, Holsboer F. CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. *Neuropsychopharmacology* 34:1494-503, 2009.
68. Shinahara M, Nishiyama M, Iwasaki Y, Nakayama S, Noguchi T, Kambayashi M, Okada Y, Tsuda M, **Stenzel-Poore MP**, Hashimoto K, Terada Y. Plasma Adiponectin Levels are Increased Despite Insulin Resistance in Corticotropin-releasing hormone transgenic mice, an animal model of cushing syndrome. *Endocr J*.56:879-886, 2009.
69. Marsh BJ, Stevens SL, Packard AEB, Gopalan B, Hunter B, Leung PY, Harrington CA, **Stenzel-Poore MP**. Systemic LPS protects the brain from ischemic injury by reprogramming the brain's response to stroke: a critical role for IRF3. *J. Neuroscience* 29:9839-9849, 2009.
70. Gresack JE, Risbrough VB, Scott CN, Coste S, **Stenzel-Poore M**, Geyer MA, Powell SB. Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. *Behav Brain Res*. 209:80-4, 2010.
71. Giardino WJ, Pastor R, Anacker AM, Spangler E, Cote DM, Li J, **Stenzel-Poore MP**, Phillips TJ, Ryabinin AE. Dissection of corticotropin-releasing factor system involvement in locomotor sensitivity to methamphetamine. *Genes Brain Behav*. 10(1):78-89, 2011.
72. McDermott JE, Archuleta M, Stevens SL, **Stenzel-Poore MP**, Sanfillippo A. Defining the players in higher-order networks: predictive modeling for reverse engineering functional influence networks. *Pac Symp Biocomput*. 314-25, 2011.
73. Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD, Hobbs TR, **Stenzel-Poore MP**. Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. *J. Cerebral Blood Flow & Metabolism* 31: 1229-42, 2011.
74. Wang L, Million M, Rivier J, Rivier C, Craft N, **Stenzel-Poore MP**, Taché Y. CRF Receptor Antagonist Astressin-B Reverses and Prevents Alopecia in CRF Over-Expressing Mice. *PLoS One*. 6(2):e16377, 2011.
75. Nakayama S, Nishiyama M, Iwasaki Y, Shinahara M, Okada Y, Tsuda M, Okazaki M, Tsugita M, Taguchi T, Makino S, **Stenzel-Poore MP**, Hashimoto K, Terada Y. Corticotropin-releasing hormone (CRH) transgenic



- mice display hyperphagia with increased Agouti-related protein mRNA in the hypothalamic arcuate nucleus. *Endocr J.* 58(4):279-86 2011.
76. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, **Stenzel-Poore MP**. Multiple preconditioning paradigms converge on interferon regulatory factor dependent signaling to promote tolerance to ischemic brain injury. *J. Neuroscience* 31: 8456-8463, 2011.
  77. Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, **Stenzel-Poore MP**. LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. *J. Neuroinflammation* 8: 140, 2011.
  78. Pastor R, Reed C, Burkhardt-Kasch S, Li N, Sharpe AL, Coste SC, **Stenzel-Poore MP**, Phillips TJ. Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout mice. *Psychopharmacology (Berl)* 218(1): 169-177, 2011.
  79. Giardino WJ, Mark GP, **Stenzel-Poore MP**, Ryabinin AE. Dissociation of corticotropin-releasing factor receptor subtype involvement in sensitivity to locomotor effects of methamphetamine and cocaine. *Psychopharmacology (Berl)*. 219(4): 1055-1063, 2012.
  80. Kaur S, Li J, **Stenzel-Poore MP**, Ryabinin AE. Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice. *Alcoholism: Clinical and Experimental Research* 36(2): 193-196, 2012.
  81. Packard AEB, Hedges JC, Bahjat FR, Stevens SL, Conlin MJ, Salazar AM, **Stenzel-Poore MP**. Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury. *Journal of Cerebral Blood Flow & Metabolism* 32: 242-247, 2012.
  82. Leung PY, Stevens SL, Packard AEB, Lessov NS, Yang T, Conrad VK, van den Dungen NNAM, Simon RP, **Stenzel-Poore MP**. TLR7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. *Stroke* 43: 1383-1389, 2012.
  83. McDermott JE, Vartanian KB, Mitchell H, Stevens SL, Sanfilippo A, **Stenzel-Poore MP**. Identification and validation of Ifit1 as an important innate immune bottleneck. *PLoS ONE* 7(6): e36465. 2012.
  84. Urbanski HF, Kohama SG, West GA, Glynn C, Williams-Karnesky RL, Earl E, Neuringer MN, Renner L, Weiss A, **Stenzel-Poore M**, Bahjat FR. Changes in spontaneous activity assessed by accelerometry correlate with extent of cerebral ischemia-reperfusion injury in the nonhuman primate. *Translational Stroke Research* published on line May 2012.
  85. Sanfilippo AP, Haack JN, McDermott JE, Stevens SL, **Stenzel-Poore MP**. Modeling Emergence in Regulatory Networks. *IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2012*.
  86. Gesuete R, Packard AEB, Vartanian KB, Conrad VK, Stevens SL, Bahjat FR, Yang T, **Stenzel-Poore MP**. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I Interferon signaling. *J. Neurochemistry* 123 Suppl 2: 75-85, 2012.
  87. Packard AEB, Leung PY, Vartanian KB, Stevens SL, Bahjat FR, **Stenzel-Poore MP**. TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning. *Journal of Cerebral Blood Flow & Metabolism* 32: 2193-2200, 2012.
  88. McDermott JE, Jarman K, Taylor R, Lancaster M, Vartanian KB, Stevens SL, **Stenzel-Poore MP**, Sanfilippo A. Modeling Dynamic Regulatory Processes in Stroke. *PLoS Computational Biology* 8(10):e1002722, 2012.
  89. Lanekoff I, Stevens SL, **Stenzel-Poore MP**, Laskin J. Matrix effects in biological mass spectrometry imaging: identification and compensation. *Analyst* DOI: 10.1039/c4an00504j, 2014.

## CHAPTERS AND REVIEWS

1. **Stenzel-Poore MP**, M. B. Rittenberg. Unequal distribution of replacement mutations in  $\kappa$  and  $\lambda$  light chains and their associated H chains: the Group II antibody response to phosphocholine-KLH. in *Somatic Mutation in V regions*, ed, E. J. Steele, CRC Press. 1990.
2. Murray SE, Coste SC, Lindberg I, **Stenzel-Poore MP**. Genetic mutants with dysregulation of corticotropin pathways, in *Transgenic Models in Endocrinology*, Kluwer Academic Publishers, 143-173, 2001.
3. **Stenzel-Poore MP**, Simon RP. Gene regulation and mechanisms of ischemic tolerance, in J Krieglstein, S Klumpp (Eds), *Pharmacology of Cerebral Ischemia*, Medpharm, Stuttgart, 2002

4. Quintos RF, Coste SC, and **Stenzel-Poore MP**. Corticotropin-releasing hormone pharmacology. In: Encyclopedia of Hormones, Vol 1; Henry HL and Norman AW, eds.; Academic Press, San Diego. (2003) pp 305-313.
5. Murray SE and **Stenzel-Poore MP**. Corticotropin-releasing hormone, stress, and the immune system. In Encyclopedia of Hormones. Vol 1; Henry, HL and Norman AW, eds.; Academic Press, San Diego. (2003) pp 325-329.
6. **Stenzel-Poore MP**, Simon RP. Lipopolysaccharide (LPS) preconditioning in stroke; a look into the neuroprotective signature, in J Krieglstein, S Klumpp (Eds), Pharmacology of Cerebral Ischemia, Medpharm, Stuttgart, 2004.
7. Coste SC, Murray SE, **Stenzel-Poore MP**. Gene targeted animals with alterations in corticotropin pathways: new insights into allostatic control. In Handbook of Stress and the Brain. Editor T. Steckler, NH Kalin and JMHM Reul, Elsevier B.V. Publishers, The Netherlands pp 51-74, 2005.
8. Harrington CA, Stevens SL, **Stenzel-Poore MP**, Simon RP. Gene expression profiling in ischemic brain injury and ischemic tolerance. In Handbook of Neurochemistry and Molecular Neurobiology. Editors: A Lajtha, PH Chan, Springer US Publishers, New York pp. 1-17, 2007.
9. Marsh BJ, **Stenzel-Poore MP**. Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Current Opinion in Pharmacology, 8:8-13, 2008.
10. Doyle KP, Simon RP, **Stenzel-Poore MP**. Mechanisms of ischemic brain damage. Neuropharmacology 55:310-18, 2008.
11. Leung PY, Packard AEB, **Stenzel-Poore MP**. It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke protection. Future Neurology, 4:201-208, 2009.
12. Marsh BJ, Williams Karnesky RL, **Stenzel-Poore MP**. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience, 158:1007-1020, 2009.
13. Williams-Karnesky RL, **Stenzel-Poore MP**. Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant. Curr Neuropharmacol. 7:217-27, 2009.
14. Vartanian K, **Stenzel-Poore M** Toll-like receptor tolerance as a mechanism for neuroprotection. Translational Stroke Research. 1(4): 252-260, 2010.
15. Bahjat FR, Vartanian KB, West A, **Stenzel-Poore MP**. "Toll-like receptor agonists as antecedent therapy for ischemic brain injury: advancing preclinical studies to the nonhuman primate," in Translational Stroke Research: from target selection to clinical trials. eds. Lapchak P and Zhang JH; Springer, New York, 2012. Chapter 10 p 205-230.
16. Vartanian KB, Stevens SL, **Stenzel-Poore MP**. "The Genomics of Preconditioning and Ischemic Tolerance," in Innate Tolerance in the CNS: Translational Neuroprotection by Pre- and Post-Conditioning. eds. Gidday J, Perez-Pinzon M, Zhang JH; Springer, New York, 2012.
17. Bahjat FR, Gesuete R, **Stenzel-Poore MP**. Steps to Translate Preconditioning from Basic Research to the Clinic. Translational Stroke Research 4(1): 89-103, 2013.
18. Bahjat FR, Gesuete R, **Stenzel-Poore MP**. "Toll-Like Receptors in Ischemic Stroke and other Acute Brain Injuries," in Immunological Mechanisms and Therapies in Brain Injuries and Stroke. 2013.
19. Gesuete R, Kohoma SG, **Stenzel-Poore MP**. Toll-Like Receptors and ischemic brain injury. *Journal of Neuropathology and Experimental Neurology* 73(5): 378-386, 2014.
20. Stevens SL, Vartanian KB, **Stenzel-Poore MP**. Reprogramming the response to stroke by preconditioning. *Stroke* in press 2014.